Developer docs
API playgroundTry for free, no card

Search company profiles

CHABIOTECH

Full company profile

uuid0044bkw

Namestring
CHABIOTECH
Legal namestring
(주)차바이오텍
Websiteurl
chabio.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

CHA Biotech Co., Ltd. (차바이오텍) is a South Korean publicly listed (KOSDAQ: CHABIO) biotechnology company founded in 2002 and headquartered in Seongnam-si, Gyeonggi-do. The company operates as a vertically integrated cell and gene therapy (CGT) platform, organized across seven business divisions: CDMO services (Matica BioLabs in Korea, Matica Biotechnology in Texas, Matica BioJapan in Tokyo, and the forthcoming 65,127 m² Cell Gene Biobank at 2nd Pangyo Techno Valley); iCord cord blood banking; BioInsurance NK cell and stem cell storage; CHAUM premium anti-aging wellness; an IT division building hospital information systems and AI/Big Data healthcare platforms; a healthcare consulting division; and a genomics/precision medicine diagnostics division. Technology foundations include 4th global ranking in stem cell patent applications, 86 patents in NK cell cultivation, the world's first vitrification technology for egg freezing (1998), and the proprietary MatiMax cell line for viral vector production.

The company generates revenue through a mix of subscription/recurring (cord blood and NK cell storage, CHAUM wellness memberships), enterprise CDMO contracts, technology transfer agreements (notably with Astellas Institute for Regenerative Medicine — USD 32 million in 2023 and KRW 54.2 billion in 2019), clinical research services, and integrated demand from the broader CHA Medical Group (91 medical centers, 14,000 employees, 1,800 doctors, 20,000 researchers across 7 countries). The R&D pipeline includes CBT101 (autologous NK cell therapy for solid tumors, FDA orphan drug designation), CordSTEM stem cell therapies (degenerative disc disease, acute stroke, premature ovarian insufficiency), and hESC-RPE therapies for ocular diseases.

CHA Biotech reported consolidated revenue of KRW 1,268,254 million (~USD 1 billion) in FY2025, a 16% CAGR over FY2019-FY2025, alongside an operating loss of KRW 48,775 million and net loss of KRW 146,708 million, reflecting heavy reinvestment in R&D and manufacturing capacity. The company is led by Vice Chairman and CEO Won Tae Cha (appointed 2026), who is positioning CHA Biotech as a focused global CGT bio company, evidenced by recent equity investments from LG CNS, Hanwha General Insurance/Hanwha Life, and a digital healthcare equity-exchange partnership with Kakao, alongside divestitures of non-core assets (CHA Vaccine Institute stake, Solidus Investment).

Short descriptiontext

CHA Biotech is a South Korean KOSDAQ-listed cell and gene therapy company operating a global CDMO network (Korea, USA, Japan) alongside cord blood banking, NK cell storage, premium wellness, and digital healthcare divisions across 7 countries, generating ~USD 1 billion in FY2025 revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
Headquarters성남시, 경기도, South Korea
HQ citystring
성남시, 경기도
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, gene therapy CDMO, cord blood banking, regenerative medicine, biopharmaceutical contract manufacturing
Industry3 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell and Gene Therapy CDMO Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model7 records
1CDMO Services
TypeSubscription Recurring
Description

Contract Development and Manufacturing Organization services for cell and gene therapies, providing full-scale GMP production and testing across Korea, USA (Matica Biotechnology in Texas), and Japan. Revenue from manufacturing services, process development, and analytical development. Consolidated revenue reached KRW 1,268,254 million in FY2025.

en.chabio.com
2Cord Blood Banking (i-Cord)
TypeSubscription Recurring
Description

Cord blood storage and banking services for hematopoietic stem cells, mesenchymal stem cells, and immune cells. Operates as the world's-standard cord blood bank with largest total assets among family cord blood banks in Korea.

chabio.com
3Bio Insurance (Cell Storage)
TypeSubscription Recurring
Description

NK cell and stem cell storage services along with anti-aging and regenerative medicine solutions. Differentiated immune cell and stem cell storage services providing cutting-edge regenerative medical solutions.

chabio.com
4CHAUM Wellness
TypeSubscription Recurring
Description

Anti-aging center providing TheraSpa, personalized fitness programs, and tailored supplements. Wellness programs focused on Refresh, Energy, and Healthy Life under the Chaum Power Aging Healthcare System.

chabio.com
5IT and Digital Healthcare
TypeSubscription Recurring
Description

Digital healthcare platforms, mobile health information solutions, telemedicine systems, and advanced hospital IT systems development and management.

chabio.com
6Consulting Services
TypeProfessional Services
Description

Healthcare business consulting for designing and operating medical models using the Power Aging Life Center concept for global expansion.

chabio.com
7Genomics and Precision Medicine
TypeSubscription Recurring
Description

Genomic research and diagnostic services including molecular genetics, cytogenetics, and reproductive genetics for precision medicine delivery.

chabio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 8 records shown
1i-Cord (아이코드)
Description

Cord blood banking services offering cord blood storage for stem cell preservation and future therapeutic use.

chabio.com
+7 more records
Core offering1 text field

CHA Biotech delivers end-to-end cell and gene therapy contract development and manufacturing (CDMO) services across Korea (Matica BioLabs, Cell Gene Biobank), the USA (Matica Biotechnology, Texas), and Japan (Matica BioJapan/TCC Tokyo). Beyond CDMO, it operates the iCord cord blood bank, Bio Insurance NK cell storage, CHAUM premium anti-aging wellness centers, genomics diagnostics, and IT/digital healthcare platforms for hospitals, serving both enterprise biotech clients and individual consumers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 79.5% of NK cell therapy patients experienced improvement or stabilization
+5 more records
Product overview1 text field

CHA Biotech operates as a diversified global bio company organized into seven distinct business divisions and a research pipeline. The core offerings span the full cell and gene therapy value chain: (1) a CDMO division providing GMP manufacturing of cell and gene therapies through Matica BioLabs (Korea), Matica Biotechnology (USA), and Matica BioJapan, plus the upcoming Cell Gene Biobank; (2) iCord, a world-standard cord blood bank leveraging proprietary cryopreservation technology; (3) Bio Insurance, a differentiated NK cell and stem cell banking and therapy service with 86 patents; (4) CHAUM, a premium anti-aging wellness center with TheraSpa, fitness, and supplement offerings; (5) an IT division developing AI and Big Data-powered digital healthcare platforms, hospital IT systems, and telemedicine; (6) a Consulting division supporting global expansion of Power Aging Life Centers; and (7) a Genomics division providing molecular genetics, cytogenetics, and reproductive genetics diagnostics for precision medicine. The R&D pipeline includes CBT101 (NK cell therapy for solid tumors), CordSTEM stem cell therapy candidates, and hESC-RPE therapies for ocular diseases.

Product and service7 records
1CDMO (Contract Development and Manufacturing Organization) Services
CategoryCDMO / Biopharmaceutical Manufacturing Services
Description

Global CDMO services offering full-cycle GMP production and testing of advanced biopharmaceuticals including cell therapies and gene therapies, across the U.S. (Matica Biotechnology, Texas), Japan (Matica BioJapan), and Korea (Matica BioLabs and forthcoming Cell Gene Biobank). Serves pharmaceutical and biotech companies needing specialized CGT manufacturing capacity, viral vector production, and process development.

2iCord Cord Blood Bank
CategoryCell Storage / Cord Blood Banking Services
Description

Advanced cord blood storage service leveraging CHA Health Systems' proprietary cryopreservation technology (vitrification). Provides cord blood banking for hematopoietic stem cells, mesenchymal stem cells, and immune cells to support treatment of leukemia, blood disorders, immune deficiencies, and regenerative medicine applications for families and individuals.

3Bio Insurance (Cell Storage & Anti-aging)
CategoryCell Storage / Anti-aging Regenerative Medicine Services
Description

Differentiated NK cell and stem cell storage service backed by 86 proprietary patents in NK cell cultivation (as of May 2024). Provides anti-aging solutions and intractable disease treatment pathways through advanced regenerative medicine technology delivered via affiliated clinics including TCC Tokyo.

4CHAUM Premium Anti-aging Wellness Center
CategoryPremium Wellness / Anti-aging Healthcare Services
Description

Korea's premier anti-aging wellness center offering comprehensive wellness programs (Refresh, Energy, Healthy Life) through the Power Aging Healthcare System. Services include TheraSpa (customized metabolic and circulatory therapy), Benefit Center (one-on-one fitness with medical consultations), and curated Supplements, delivered via membership-based programs to affluent individual consumers.

5IT Division (Digital Healthcare Solutions)
CategoryHealthcare IT / Digital Health Platforms
Description

Medical IT and digital healthcare solutions merging healthcare expertise with AI and Big Data. Develops telemedicine platforms, clinical data warehouses (CDW), patient identification systems, hospital information systems (HIS), mobile health applications, and corporate health check-up management platforms for hospitals and healthcare organizations. Supports multilingual and global payment operations.

6Consulting Division (Healthcare Facility Consulting)
CategoryHealthcare Consulting Services
Description

Healthcare business consulting services leveraging the Power Aging Life Center model, covering feasibility studies, pre-operation consulting (financial modeling, organizational design), and ongoing operation and management consulting including quarterly and annual performance reviews, new medical technology adoption, and telemedicine implementation for global clients.

7Genomics Division (Precision Medicine Diagnostics)
CategoryGenomic Diagnostics / Precision Medicine Services
Description

Precision medicine through genomic research and diagnostics, operating three specialized laboratories: Molecular Genetics Laboratory (prenatal screening and genetic disease diagnostics using next-generation sequencing), Cytogenetics Laboratory (30+ years of chromosomal analysis expertise), and Reproductive Genetics Laboratory (pre-implantation genetic testing). Services are available to individuals, fertility clinics, and healthcare providers.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Collaboration on CAR-NK cell therapy development. Also collaborated on automated large-scale manufacturing process development for CAR-NK cells with Miltenyi Biotec Korea.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Strategic collaboration to build global biotech research infrastructure for K-Bio CIC (K-Bio Center for Innovation in Cell and Gene Therapy).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Comprehensive joint R&D agreement through Matica Biotechnology for CGT research and development. Includes CDMO services through Texas A&M's CIADM program. Strategic agreement signed for CGT R&D.

4VaxDome (USA)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Joint development of antiviral hybrid vaccine with VaxDome. Partnership announced in 2026.

en.chabio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Strategic partnership in digital healthcare through equity exchange. CHA Bio Group formed partnership with Kakao in digital healthcare.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaboration on pediatric brain tumor therapy development with US-based Treovir.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

MOU signed for global stem cell line establishment and large-scale manufacturing process development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-01
Description

USD 32 million technology transfer agreement signed with Astellas Institute for Regenerative Medicine, a subsidiary of Japan's Astellas Pharma, for stem cell/regenerative medicine technology. Additionally, technology transfer to AIRM generated KRW 54.2 billion in technology commercialization revenue in 2019.

9CHA Vaccine Institute
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Joint development with CHA Vaccine Institute on cancer therapy combining NK cells and immune boosters.

en.chabio.com
10Centenaire Biosciences
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Material transfer agreement for NK cell therapy combination therapies with Centenaire Biosciences. Expanded collaboration for combination studies involving NK cells and antibodies.

en.chabio.com
Strategic tierCoreTypeOthers
Description

Related academic institution within CHA Medical Group ecosystem for research and talent development.

Strategic tierCoreTypeOthers
Description

Core medical institution within CHA network providing clinical trial capabilities and healthcare services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

US-headquartered global life sciences incumbent operating Patheon CDMO plus the largest bioproduction tools/supplies portfolio (cell culture media, single-use bioreactors, viral vector production systems). Direct CGT commercial partner of CHA Biotech (K-Bio CIC build-out) and broader comparable given Patheon's contract manufacturing scale.

TypeDirect peer
Description

Tokyo-based global CDMO with growing cell and gene therapy manufacturing capacity across the US, Europe, and Asia. Directly comparable as a multi-region CDMO serving pharma and biotech clients for biologics and advanced therapies, including viral vector production similar to CHA's Matica Bio platform.

TypeDirect peer
Description

Japan-headquartered global CDMO (Fujifilm subsidiary) operating viral vector, cell therapy, and biologics manufacturing capacity in the US, UK, and Japan. Comparable multi-modality CGT manufacturing peer with explicit presence in viral vector production analogous to CHA's Matica Bio / Cell Gene Biobank platform.

TypeRegional player
Description

KOSDAQ-listed Korean vaccines and biopharmaceutical manufacturer with GMP-scale production facilities and ongoing development of cell and gene therapy capabilities. Comparable Korean domestic CDMO/biologics manufacturer with overlapping client base in the Korean life sciences ecosystem.

TypeEmerging player
Description

China-based global CDMO with significant cell and gene therapy capabilities including viral vector and cell therapy manufacturing. Comparable emerging large-scale CGT manufacturing peer for CHA Biotech in the Asia-Pacific CDMO market segment.

TypeDirect peer
Description

Korean cell therapy company under the Green Cross Holdings umbrella focused on NK and immune cell therapy development and manufacturing. Closest Korean domestic peer on the cell therapy product side, sharing the Korean GMP regulatory framework with CHA Biotech's Matica BioLabs.

TypeDirect peer
Description

US-headquartered global CDMO with major cell therapy (via the former Paragon Gene Therapy / Acquired by Novo Holdings 2024) and viral vector capabilities. Highly comparable to CHA Biotech as a one-stop CDMO offering process development, GMP manufacturing, and fill-finish for cell and gene therapies.

TypeDirect peer
Description

Swiss-headquartered global CDMO leader with the largest cell & gene therapy CDMO franchise (Lonza Cell & Gene Technologies). Closest large-scale comparable to CHA Biotech's Matica BioLabs / Matica Biotechnology / Matica BioJapan network in terms of autologous/allogeneic cell therapy and viral vector manufacturing for clinical and commercial supply.

TypeEmerging player
Description

KOSDAQ-listed Korean stem cell therapy company developing allogeneic stem cell-based treatments for atopic dermatitis and osteoarthritis. Comparable Korean domestic peer in the stem cell therapy space with overlapping R&D focus to CHA Biotech's CordSTEM family.

TypeDirect peer
Description

KOSDAQ-listed Korean biologics CDMO operating one of the world's largest single-site mammalian cell culture capacities in Songdo, with explicit expansion into CGT/adeno-associated virus manufacturing. Comparable domestic Korean CDMO peer for CHA Biotech's Matica BioLabs and the upcoming Cell Gene Biobank.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries12 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CHABIOTECH

Cell and Gene Therapy CDMO Serviceschabio.com

CHA Biotech is a South Korean KOSDAQ-listed cell and gene therapy company operating a global CDMO network (Korea, USA, Japan) alongside cord blood banking, NK cell storage, premium wellness, and digital healthcare divisions across 7 countries, generating ~USD 1 billion in FY2025 revenue.

What CHABIOTECH does

CHA Biotech Co., Ltd. (차바이오텍) is a South Korean publicly listed (KOSDAQ: CHABIO) biotechnology company founded in 2002 and headquartered in Seongnam-si, Gyeonggi-do. The company operates as a vertically integrated cell and gene therapy (CGT) platform, organized across seven business divisions: CDMO services (Matica BioLabs in Korea, Matica Biotechnology in Texas, Matica BioJapan in Tokyo, and the forthcoming 65,127 m² Cell Gene Biobank at 2nd Pangyo Techno Valley); iCord cord blood banking; BioInsurance NK cell and stem cell storage; CHAUM premium anti-aging wellness; an IT division building hospital information systems and AI/Big Data healthcare platforms; a healthcare consulting division; and a genomics/precision medicine diagnostics division. Technology foundations include 4th global ranking in stem cell patent applications, 86 patents in NK cell cultivation, the world's first vitrification technology for egg freezing (1998), and the proprietary MatiMax cell line for viral vector production.

The company generates revenue through a mix of subscription/recurring (cord blood and NK cell storage, CHAUM wellness memberships), enterprise CDMO contracts, technology transfer agreements (notably with Astellas Institute for Regenerative Medicine — USD 32 million in 2023 and KRW 54.2 billion in 2019), clinical research services, and integrated demand from the broader CHA Medical Group (91 medical centers, 14,000 employees, 1,800 doctors, 20,000 researchers across 7 countries). The R&D pipeline includes CBT101 (autologous NK cell therapy for solid tumors, FDA orphan drug designation), CordSTEM stem cell therapies (degenerative disc disease, acute stroke, premature ovarian insufficiency), and hESC-RPE therapies for ocular diseases.

CHA Biotech reported consolidated revenue of KRW 1,268,254 million (~USD 1 billion) in FY2025, a 16% CAGR over FY2019-FY2025, alongside an operating loss of KRW 48,775 million and net loss of KRW 146,708 million, reflecting heavy reinvestment in R&D and manufacturing capacity. The company is led by Vice Chairman and CEO Won Tae Cha (appointed 2026), who is positioning CHA Biotech as a focused global CGT bio company, evidenced by recent equity investments from LG CNS, Hanwha General Insurance/Hanwha Life, and a digital healthcare equity-exchange partnership with Kakao, alongside divestitures of non-core assets (CHA Vaccine Institute stake, Solidus Investment).

CHABIOTECH firmographics

Firmographics
Name
CHABIOTECH
Legal name
(주)차바이오텍
Website
https://chabio.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
CHA Biotech is a South Korean KOSDAQ-listed cell and gene therapy company operating a global CDMO network (Korea, USA, Japan) alongside cord blood banking, NK cell storage, premium wellness, and digital healthcare divisions across 7 countries, generating ~USD 1 billion in FY2025 revenue.
Ownership category
akta.pro rank

CHABIOTECH industry classification

Industry
Product category
Cell and Gene Therapy CDMO Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell therapy manufacturing
  • Gene therapy CDMO
  • Cord blood banking
  • Regenerative medicine
  • Biopharmaceutical contract manufacturing

Where CHABIOTECH is headquartered

Location

Headquarters

HQ city
성남시, 경기도
HQ country
South Korea
HQ region
Asia

Offices9 records

Markets served

CHABIOTECH business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO Services: Contract Development and Manufacturing Organization services for cell and gene therapies, providing full-scale GMP production and testing across Korea, USA (Matica Biotechnology in Texas), and Japan. Revenue from manufacturing services, process development, and analytical development. Consolidated revenue reached KRW 1,268,254 million in FY2025.
  2. Cord Blood Banking (i-Cord): Cord blood storage and banking services for hematopoietic stem cells, mesenchymal stem cells, and immune cells. Operates as the world's-standard cord blood bank with largest total assets among family cord blood banks in Korea.
  3. Bio Insurance (Cell Storage): NK cell and stem cell storage services along with anti-aging and regenerative medicine solutions. Differentiated immune cell and stem cell storage services providing cutting-edge regenerative medical solutions.
  4. CHAUM Wellness: Anti-aging center providing TheraSpa, personalized fitness programs, and tailored supplements. Wellness programs focused on Refresh, Energy, and Healthy Life under the Chaum Power Aging Healthcare System.
  5. IT and Digital Healthcare: Digital healthcare platforms, mobile health information solutions, telemedicine systems, and advanced hospital IT systems development and management.
  6. Consulting Services: Healthcare business consulting for designing and operating medical models using the Power Aging Life Center concept for global expansion.
  7. Genomics and Precision Medicine: Genomic research and diagnostic services including molecular genetics, cytogenetics, and reproductive genetics for precision medicine delivery.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

CHABIOTECH product offering

Product offering

Core offering

CHA Biotech delivers end-to-end cell and gene therapy contract development and manufacturing (CDMO) services across Korea (Matica BioLabs, Cell Gene Biobank), the USA (Matica Biotechnology, Texas), and Japan (Matica BioJapan/TCC Tokyo). Beyond CDMO, it operates the iCord cord blood bank, Bio Insurance NK cell storage, CHAUM premium anti-aging wellness centers, genomics diagnostics, and IT/digital healthcare platforms for hospitals, serving both enterprise biotech clients and individual consumers globally.

Product overview

CHA Biotech operates as a diversified global bio company organized into seven distinct business divisions and a research pipeline. The core offerings span the full cell and gene therapy value chain: (1) a CDMO division providing GMP manufacturing of cell and gene therapies through Matica BioLabs (Korea), Matica Biotechnology (USA), and Matica BioJapan, plus the upcoming Cell Gene Biobank; (2) iCord, a world-standard cord blood bank leveraging proprietary cryopreservation technology; (3) Bio Insurance, a differentiated NK cell and stem cell banking and therapy service with 86 patents; (4) CHAUM, a premium anti-aging wellness center with TheraSpa, fitness, and supplement offerings; (5) an IT division developing AI and Big Data-powered digital healthcare platforms, hospital IT systems, and telemedicine; (6) a Consulting division supporting global expansion of Power Aging Life Centers; and (7) a Genomics division providing molecular genetics, cytogenetics, and reproductive genetics diagnostics for precision medicine. The R&D pipeline includes CBT101 (NK cell therapy for solid tumors), CordSTEM stem cell therapy candidates, and hESC-RPE therapies for ocular diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • i-Cord (아이코드): Cord blood banking services offering cord blood storage for stem cell preservation and future therapeutic use.
  • BioInsurance (셀 인슈어런스)
  • CHAUM (차움)
  • Matica BioLabs (마티카바이오랩스)
  • Matica Biotechnology
  • TCC Tokyo (Total Cell Clinic)
  • CordSTEM
  • CBT101

Products and services

  • CDMO (Contract Development and Manufacturing Organization) Services Global CDMO services offering full-cycle GMP production and testing of advanced biopharmaceuticals including cell therapies and gene therapies, across the U.S. (Matica Biotechnology, Texas), Japan (Matica BioJapan), and Korea (Matica BioLabs and forthcoming Cell Gene Biobank). Serves pharmaceutical and biotech companies needing specialized CGT manufacturing capacity, viral vector production, and process development.
  • iCord Cord Blood Bank Advanced cord blood storage service leveraging CHA Health Systems' proprietary cryopreservation technology (vitrification). Provides cord blood banking for hematopoietic stem cells, mesenchymal stem cells, and immune cells to support treatment of leukemia, blood disorders, immune deficiencies, and regenerative medicine applications for families and individuals.
  • Bio Insurance (Cell Storage & Anti-aging) Differentiated NK cell and stem cell storage service backed by 86 proprietary patents in NK cell cultivation (as of May 2024). Provides anti-aging solutions and intractable disease treatment pathways through advanced regenerative medicine technology delivered via affiliated clinics including TCC Tokyo.
  • CHAUM Premium Anti-aging Wellness Center Korea's premier anti-aging wellness center offering comprehensive wellness programs (Refresh, Energy, Healthy Life) through the Power Aging Healthcare System. Services include TheraSpa (customized metabolic and circulatory therapy), Benefit Center (one-on-one fitness with medical consultations), and curated Supplements, delivered via membership-based programs to affluent individual consumers.
  • IT Division (Digital Healthcare Solutions) Medical IT and digital healthcare solutions merging healthcare expertise with AI and Big Data. Develops telemedicine platforms, clinical data warehouses (CDW), patient identification systems, hospital information systems (HIS), mobile health applications, and corporate health check-up management platforms for hospitals and healthcare organizations. Supports multilingual and global payment operations.
  • Consulting Division (Healthcare Facility Consulting) Healthcare business consulting services leveraging the Power Aging Life Center model, covering feasibility studies, pre-operation consulting (financial modeling, organizational design), and ongoing operation and management consulting including quarterly and annual performance reviews, new medical technology adoption, and telemedicine implementation for global clients.
  • Genomics Division (Precision Medicine Diagnostics) Precision medicine through genomic research and diagnostics, operating three specialized laboratories: Molecular Genetics Laboratory (prenatal screening and genetic disease diagnostics using next-generation sequencing), Cytogenetics Laboratory (30+ years of chromosomal analysis expertise), and Reproductive Genetics Laboratory (pre-implantation genetic testing). Services are available to individuals, fertility clinics, and healthcare providers.

Quantifiable outcome

  • 79.5% of NK cell therapy patients experienced improvement or stabilization
  • +5 more outcomes

Companies that use CHABIOTECH

Customer profile

Named customers11 records

Segments6 records

Ideal customer profiles4 records

CHABIOTECH technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

CHABIOTECH partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • Miltenyi BioteccoreStrategic or Co-development Partner · 1 January 2026Collaboration on CAR-NK cell therapy development. Also collaborated on automated large-scale manufacturing process development for CAR-NK cells with Miltenyi Biotec Korea.
  • Thermo Fisher ScientificcoreStrategic or Co-development Partner · 1 January 2026Strategic collaboration to build global biotech research infrastructure for K-Bio CIC (K-Bio Center for Innovation in Cell and Gene Therapy).
  • Texas A&M UniversitycoreStrategic or Co-development Partner · 1 January 2026Comprehensive joint R&D agreement through Matica Biotechnology for CGT research and development. Includes CDMO services through Texas A&M's CIADM program. Strategic agreement signed for CGT R&D.
  • VaxDome (USA)minorStrategic or Co-development Partner · 1 January 2026Joint development of antiviral hybrid vaccine with VaxDome. Partnership announced in 2026.
  • KakaocoreStrategic or Co-development Partner · 1 January 2025Strategic partnership in digital healthcare through equity exchange. CHA Bio Group formed partnership with Kakao in digital healthcare.
  • Treovir (USA)minorStrategic or Co-development Partner · 1 January 2024Collaboration on pediatric brain tumor therapy development with US-based Treovir.
  • Sartorius Korea BiotechminorStrategic or Co-development Partner · 1 January 2024MOU signed for global stem cell line establishment and large-scale manufacturing process development.
  • Astellas Institute for Regenerative Medicine (AIRM)coreTechnology or Integration · 1 January 2023USD 32 million technology transfer agreement signed with Astellas Institute for Regenerative Medicine, a subsidiary of Japan's Astellas Pharma, for stem cell/regenerative medicine technology. Additionally, technology transfer to AIRM generated KRW 54.2 billion in technology commercialization revenue in 2019.
  • CHA Vaccine InstituteminorStrategic or Co-development Partner · 1 January 2023Joint development with CHA Vaccine Institute on cancer therapy combining NK cells and immune boosters.
  • Centenaire BiosciencesminorStrategic or Co-development Partner · 1 January 2021Material transfer agreement for NK cell therapy combination therapies with Centenaire Biosciences. Expanded collaboration for combination studies involving NK cells and antibodies.
  • CHA University (차 의과학대학교)coreOthersRelated academic institution within CHA Medical Group ecosystem for research and talent development.
  • CHA Medical Center (차병원)coreOthersCore medical institution within CHA network providing clinical trial capabilities and healthcare services.

Scale indicators16 records

Recent moves6 records

Expansion highlights7 records

CHABIOTECH competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific Inc. US-headquartered global life sciences incumbent operating Patheon CDMO plus the largest bioproduction tools/supplies portfolio (cell culture media, single-use bioreactors, viral vector production systems). Direct CGT commercial partner of CHA Biotech (K-Bio CIC build-out) and broader comparable given Patheon's contract manufacturing scale.

Direct peers

  • AGC Biologics: Tokyo-based global CDMO with growing cell and gene therapy manufacturing capacity across the US, Europe, and Asia. Directly comparable as a multi-region CDMO serving pharma and biotech clients for biologics and advanced therapies, including viral vector production similar to CHA's Matica Bio platform.
  • FUJIFILM Diosynth Biotechnologies: Japan-headquartered global CDMO (Fujifilm subsidiary) operating viral vector, cell therapy, and biologics manufacturing capacity in the US, UK, and Japan. Comparable multi-modality CGT manufacturing peer with explicit presence in viral vector production analogous to CHA's Matica Bio / Cell Gene Biobank platform.
  • GC Cell (Green Cross Cell): Korean cell therapy company under the Green Cross Holdings umbrella focused on NK and immune cell therapy development and manufacturing. Closest Korean domestic peer on the cell therapy product side, sharing the Korean GMP regulatory framework with CHA Biotech's Matica BioLabs.
  • Catalent, Inc. US-headquartered global CDMO with major cell therapy (via the former Paragon Gene Therapy / Acquired by Novo Holdings 2024) and viral vector capabilities. Highly comparable to CHA Biotech as a one-stop CDMO offering process development, GMP manufacturing, and fill-finish for cell and gene therapies.
  • Lonza Group AG: Swiss-headquartered global CDMO leader with the largest cell & gene therapy CDMO franchise (Lonza Cell & Gene Technologies). Closest large-scale comparable to CHA Biotech's Matica BioLabs / Matica Biotechnology / Matica BioJapan network in terms of autologous/allogeneic cell therapy and viral vector manufacturing for clinical and commercial supply.
  • Samsung Biologics Co., Ltd. KOSDAQ-listed Korean biologics CDMO operating one of the world's largest single-site mammalian cell culture capacities in Songdo, with explicit expansion into CGT/adeno-associated virus manufacturing. Comparable domestic Korean CDMO peer for CHA Biotech's Matica BioLabs and the upcoming Cell Gene Biobank.

Regional players

  • SK Bioscience Co., Ltd. KOSDAQ-listed Korean vaccines and biopharmaceutical manufacturer with GMP-scale production facilities and ongoing development of cell and gene therapy capabilities. Comparable Korean domestic CDMO/biologics manufacturer with overlapping client base in the Korean life sciences ecosystem.

Emerging players

  • WuXi Advanced Therapies (WuXi AppTec): China-based global CDMO with significant cell and gene therapy capabilities including viral vector and cell therapy manufacturing. Comparable emerging large-scale CGT manufacturing peer for CHA Biotech in the Asia-Pacific CDMO market segment.
  • Kangstem Biotech Co., Ltd. KOSDAQ-listed Korean stem cell therapy company developing allogeneic stem cell-based treatments for atopic dermatitis and osteoarthritis. Comparable Korean domestic peer in the stem cell therapy space with overlapping R&D focus to CHA Biotech's CordSTEM family.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

CHABIOTECH social profiles

Digital presence

CHABIOTECH compliance and trust

Trust signal

Compliance2 records

CHABIOTECH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CHABIOTECH leadership team

Management profile

Number of profiles

Profiles5 records

CHABIOTECH subsidiaries and ownership

Company hierarchy

Subsidiaries12 records

CHABIOTECH funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CHABIOTECH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CHABIOTECH

What does CHABIOTECH do?

CHA Biotech delivers end-to-end cell and gene therapy contract development and manufacturing (CDMO) services across Korea (Matica BioLabs, Cell Gene Biobank), the USA (Matica Biotechnology, Texas), and Japan (Matica BioJapan/TCC Tokyo). Beyond CDMO, it operates the iCord cord blood bank, Bio Insurance NK cell storage, CHAUM premium anti-aging wellness centers, genomics diagnostics, and IT/digital healthcare platforms for hospitals, serving both enterprise biotech clients and individual consumers globally.

Is CHABIOTECH a public or private company?

CHABIOTECH is a public company. It is classified as public and is currently operating.

When was CHABIOTECH founded?

CHABIOTECH was founded in 2002. It employs 11 to 50 people.

Where is CHABIOTECH based?

CHABIOTECH is headquartered in 성남시, 경기도, South Korea, in the Asia region.

How does CHABIOTECH make money?

Seven revenue lines are on record. CDMO Services are the primary driver. The others are cord Blood Banking (i-Cord), bio Insurance (Cell Storage), CHAUM Wellness, IT and Digital Healthcare, consulting Services and genomics and Precision Medicine.

Who are CHABIOTECH's main competitors?

Thermo Fisher Scientific Inc. is listed as a broad incumbent. Direct peers are AGC Biologics, FUJIFILM Diosynth Biotechnologies, GC Cell (Green Cross Cell), Catalent, Inc., Lonza Group AG and Samsung Biologics Co., Ltd.. SK Bioscience Co., Ltd. is listed as a regional player. Emerging players are WuXi Advanced Therapies (WuXi AppTec) and Kangstem Biotech Co., Ltd..

Does CHABIOTECH have an API?

No public API is recorded for CHABIOTECH.

What industry is CHABIOTECH in?

CHABIOTECH's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals